New Rybelsus Tablet Formulation
Novo Nordisk UK is introducing a new formulation of Rybelsus with increased bioavailability, which is bioequivalent to the current formulation but at lower doses.
| Initial Formulation (Oval Tablet) | Bioequivalent | New Formulation (Round Tablet) |
|---|---|---|
| 3 mg (starting dose) | = | 1.5 mg (starting dose) |
| 7 mg (maintenance dose) | = | 4 mg (maintenance dose) |
| 14 mg (maintenance dose) | = | 9 mg (maintenance dose) |
The two formulations will temporarily co-exist on the market, which may cause mix-ups. This could result in overdosing, which increases the risk of adverse events.
Patients must be informed of the change when prescribing or dispensing. Any new patients should be started on the new formulation.
Tablet and Packaging Differences
Tablets for the new formulation are smaller in size and have a different shape (round). Tablets are debossed with strength.
The cartons and blister strips for the new formulation tablets are smaller than the initial versions
Actions for Pharmacy Teams:
- Confirm the correct strength is being prescribed and dispensed and advise patients on the change using the Information sheet, which can be downloaded here:
- Report suspected Adverse Drug Reactions via the Yellow Card Scheme and any patient safety incidents via your usual process
For Medicine Information questions - contact Novo Nordisk 0800 023 2573